Knocking down METTL3 expression in pancreatic cancer cell lines enhances their sensitivity to anticancer radiotherapy and chemotherapeutics such as gemcitabine, cisplatin, and 5-fluorouracil [187]. The gene discussed is METTL3; the disease is pancreatic neoplasm.